Abstract
IntroductionThere has been growing evidence to support the hypothesis that inflammation is involved in the pathogenesis of schizophrenia.ObjectivesThe aim of the present literature review was to assess the efficacy of acetylsalicylic acid (ASA) as an adjuvant agent in the treatment of an acute exacerbation of schizophrenia.MethodsWe searched randomized clinical trials based on regular searches of MEDLINE, Embase, PubMed.ResultsWe included four studies. The results were in favor of the efficacy of ASA in the study where authors targeted early psychosis. Illness duration seems to predict response to anti-inflammatory agents.ConclusionsFurther studies of early stages of schizophrenia are helpful.Disclosure of InterestNone Declared
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
